InsidersTradesSigma
Innoviva, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the Innoviva, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Innoviva, Inc. has logged 27 public disclosures. Market capitalisation: €1.6bn. The latest transaction was reported on 23 May 2022 (Attribution). Among the most active insiders: Zhen Marianne. The full history is openly available.
27
Insider Decl.
0
Thresholds
€212,132
2 ops.
Buy Volume
€321m
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Innoviva, Inc. Buy (bullish), based on 4 analysts. Average price target: US$35.50.
36Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 96 of 25,750 companies
90.2
score / 100
Value90
Quality91
FCF yld11%
Earn yld16%
EV/EBITDA5.2x
ROE51%
Gross mgn81%
Net mgn66%
Debt/EBITDA0.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 23 May 2022
Declarations27 total
1,834 shares0Common StockSEC:0001567619-22-011518:0
12,647 shares0Common StockSEC:0001567619-22-009042:0
12,647 shares0Common StockSEC:0001567619-22-009046:0
12,647 shares0Common StockSEC:0001567619-22-009041:0
12,647 shares0Common StockSEC:0001567619-22-009045:0
12,647 shares0Common StockSEC:0001567619-22-009043:0
12,647 shares0Common StockSEC:0001567619-22-009044:0
6,691 shares0Common StockSEC:0001567619-22-006130:0
2,277 shares@ US$19.990.0025% mcap21.4% of flowCommon StockSEC:0001567619-22-005277:0
758 shares@ US$17.0515.5% of flowCommon StockSEC:0001567619-21-020984
758 shares@ US$17.050.0007% mcap6.1% of flowCommon StockSEC:0001567619-21-020984:0
1,129 shares@ US$15.890.0009% mcap8.2% of flowCommon StockSEC:0001567619-21-016263:0
1,129 shares@ US$15.8920.9% of flowCommon StockSEC:0001567619-21-016263
2,802 shares@ US$16.020.0024% mcap20.6% of flowCommon StockSEC:0001567619-21-016236:0
2,802 shares@ US$16.0252.3% of flowCommon StockSEC:0001567619-21-016236
10,000 shares@ US$12.96750.0% of flowCommon StockSEC:0001567619-21-011167
Ideal exit: 15 Feb 2022 (T+270)
10,000 shares@ US$12.9670.0065% mcap50.0% of flowCommon StockSEC:0001567619-21-011167:0
Ideal exit: 15 Feb 2022 (T+270)
759 shares@ US$13.320.0005% mcap4.4% of flowCommon StockSEC:0001567619-21-011058:0
759 shares@ US$13.324.4% of flowCommon StockSEC:0001567619-21-011058
32,005,260 shares@ US$12.2519.78% mcap100.0% of flowCommon StockSEC:0001387131-21-006039:0
17,482 shares0Common StockSEC:0001567619-21-010826:0
17,482 shares0Common StockSEC:0001567619-21-010828
17,482 shares0Common StockSEC:0001567619-21-010828:0
17,482 shares0Common StockSEC:0001567619-21-010829:0
17,482 shares0Common StockSEC:0001567619-21-010830:0
25 of 27 declarations
About Innoviva, Inc.
Innoviva, Inc. is a United States-based biopharmaceutical company listed on the NASDAQ (United States). Its business model is unusual for the pharma sector because it combines royalty income, a hospital-focused specialty therapeutics platform, and a portfolio of strategic healthcare investments. The company was originally incorporated in 1996 as Advanced Medicine, Inc., later operated under the Theravance name, and was rebranded as Innoviva in 2016. Its headquarters are in Burlingame, California. Innoviva was initially formed to maximize the value of royalty streams from respiratory products co-developed with and licensed to GSK. Over time, management broadened the strategy beyond passive royalty collection toward a more active healthcare asset platform. Today the company is organized around three main pillars. First, it owns a durable royalty portfolio tied to legacy respiratory medicines associated with GSK. Second, it operates Innoviva Specialty Therapeutics (IST), a commercial platform focused on critical care and infectious disease. Third, it holds strategic investments in healthcare-related assets, which adds optionality and may support long-term capital appreciation. From a product perspective, IST markets GIAPREZA®, XERAVA®, XACDURO®, and ZEVTERA®, and the business recently added NUZOLVENCE® following U.S. regulatory approval. This gives Innoviva exposure to unmet medical needs in hospital care and anti-infective therapy, areas where clinical differentiation and regulatory barriers matter more than pure scale. The competitive environment is still intense, especially in infectious diseases, but Innoviva’s portfolio is differentiated by a mix of legacy royalties and newly commercialized specialty products rather than dependence on a single drug. Geographically, the company remains primarily U.S.-centric, with most operations and revenue generation anchored in the United States, although some products and licensing relationships can have broader international relevance depending on the asset and indication. Recent milestones are important for investors: in February 2026, Innoviva reported full-year 2025 results showing revenue growth and higher net income; it highlighted the mid-2025 U.S. launch of ZEVTERA; and it disclosed FDA approval of NUZOLVENCE in late 2025. Innoviva also initiated a $125 million share repurchase program, which may be of particular interest to investors tracking insider ownership changes and SEC Form 4 activity.
